Search research articles
Contact Us
Filters
Showing results (31-40 of 67) with videos related to
Page
of 7
Sort By:
Journal of Medicinal Chemistry
|
February 3, 2023
Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity <i>In Vivo</i> in Acute Myeloid Leukemia
Atsunori Kaneshige, Longchuan Bai, Mi Wang, et al.
Journal of Medicinal Chemistry
|
April 6, 2011
Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity
Haiying Sun, Liu Liu, Jianfeng Lu, et al.
Journal of Medicinal Chemistry
|
June 9, 2012
Correction to Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold
Haibin Zhou, Jianfang Chen, Jennifer L Meagher, et al.
Journal of Medicinal Chemistry
|
March 28, 2012
Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold
Haibin Zhou, Jianfang Chen, Jennifer L Meagher, et al.
Journal of Medicinal Chemistry
|
June 13, 2025
MD-4251: A First-in-Class Oral MDM2 Degrader Inducing Complete Tumor Regression with Single-Dose Administration
Ranjan Kumar Acharyya, Liyue Huang, Angelo Aguilar, et al.
Journal of Medicinal Chemistry
|
March 23, 2026
Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader
Dimin Wu, Haibin Zhou, Longchuan Bai, et al.
Molecular Cancer Therapeutics
|
February 2, 2011
Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases
Jie Yang, Donna McEachern, Wenyan Li, et al.
ACS Medicinal Chemistry Letters
|
June 18, 2021
SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression
Haibin Zhou, Longchuan Bai, Renqi Xu, et al.
Journal of Medicinal Chemistry
|
August 12, 2024
Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9
Changwei Wang, Mi Wang, Yu Wang, et al.
Cancer Research
|
November 18, 2008
SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP
Jianfeng Lu, Longchuan Bai, Haiying Sun, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 67) with videos related to
Sort By:
Page
of 7
Journal of Medicinal Chemistry
|
February 3, 2023
Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity <i>In Vivo</i> in Acute Myeloid Leukemia
Atsunori Kaneshige, Longchuan Bai, Mi Wang, et al.
Journal of Medicinal Chemistry
|
April 6, 2011
Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity
Haiying Sun, Liu Liu, Jianfeng Lu, et al.
Journal of Medicinal Chemistry
|
June 9, 2012
Correction to Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold
Haibin Zhou, Jianfang Chen, Jennifer L Meagher, et al.
Journal of Medicinal Chemistry
|
March 28, 2012
Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold
Haibin Zhou, Jianfang Chen, Jennifer L Meagher, et al.
Journal of Medicinal Chemistry
|
June 13, 2025
MD-4251: A First-in-Class Oral MDM2 Degrader Inducing Complete Tumor Regression with Single-Dose Administration
Ranjan Kumar Acharyya, Liyue Huang, Angelo Aguilar, et al.
Journal of Medicinal Chemistry
|
March 23, 2026
Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader
Dimin Wu, Haibin Zhou, Longchuan Bai, et al.
Molecular Cancer Therapeutics
|
February 2, 2011
Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases
Jie Yang, Donna McEachern, Wenyan Li, et al.
ACS Medicinal Chemistry Letters
|
June 18, 2021
SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression
Haibin Zhou, Longchuan Bai, Renqi Xu, et al.
Journal of Medicinal Chemistry
|
August 12, 2024
Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9
Changwei Wang, Mi Wang, Yu Wang, et al.
Cancer Research
|
November 18, 2008
SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP
Jianfeng Lu, Longchuan Bai, Haiying Sun, et al.
Page
of 7